Pfizer, Inc. (PFE) Position Raised by Fisher Asset Management LLC
Fisher Asset Management LLC increased its position in shares of Pfizer, Inc. (NYSE:PFE) by 3.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,035,362 shares of the biopharmaceutical company’s stock after purchasing an additional 1,275,832 shares during the quarter. Pfizer accounts for approximately 1.7% of Fisher Asset Management LLC’s investment portfolio, making the stock its 11th largest position. Fisher Asset Management LLC owned 0.57% of Pfizer worth $1,143,248,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Asset Planning Services Ltd. lifted its position in Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new stake in Pfizer during the first quarter worth about $121,000. Patten Group Inc. lifted its position in Pfizer by 5.1% during the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 252 shares during the period. Acropolis Investment Management LLC lifted its position in Pfizer by 6.7% during the second quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 352 shares during the period. Finally, Kimelman & Baird LLC bought a new stake in Pfizer during the first quarter worth about $203,000. 69.00% of the stock is owned by institutional investors and hedge funds.
In other Pfizer news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares in the company, valued at $4,492,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 in the last quarter. Corporate insiders own 0.06% of the company’s stock.
Several research firms recently weighed in on PFE. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, September 19th. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a report on Wednesday, September 13th. Finally, Jefferies Group LLC set a $37.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, September 18th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $38.21.
Pfizer, Inc. (PFE) traded down 0.3215% during mid-day trading on Thursday, reaching $35.8444. 5,601,574 shares of the company’s stock were exchanged. Pfizer, Inc. has a one year low of $29.83 and a one year high of $36.24. The stock has a 50-day moving average of $34.55 and a 200-day moving average of $33.66. The stock has a market cap of $213.18 billion, a price-to-earnings ratio of 26.2212 and a beta of 1.00. Pfizer also saw unusually large options trading on Monday. Stock traders acquired 24,211 call options on the company. This represents an increase of approximately 129% compared to the average daily volume of 10,577 call options.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company posted $0.64 EPS. Pfizer’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.56%. Pfizer’s payout ratio is currently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.